[Efficacy and safety of ustekinumab in psoriatic arthritis after anti-TNFα failure in routine practice].
Evaluation of effectiveness and safety of ustekinumab in psoriatic arthritis after anti-TNFα failure. We conducted a retrospective and monocentric study. The evaluation of articular and cutaneous effectiveness by the patient was made with numeric scale and satisfaction scale and by the physician during a rhumatological-dermatological consultation. The safety was analyzed by collecting the adverse effects. Nine patients with anti-TNF failure were included. Five of them stopped the treatment because of severe adverse effects. The mean duration treatment of ustekinumab was 24 months. Articular and cutaneous effectiveness were respectively 4.4/10 and 6.7/10. Two thirds of the patients were "satisfied" and one third could stop any analgesic treatment. The mean PASI score decreased from 8.4 to 1.7 after 3 months treatment. Only minor adverse effects were collected and there were no recidivism of the adverse effects observed with anti-TNFα. Ustekinumab is an effective and safe alternative for patients with anti-TNFα failure in psoriatic arthritis.